The detection and measurement of hypoxic cells in solid tumors
- PMID: 6333921
- DOI: 10.1002/1097-0142(19841201)54:11<2441::aid-cncr2820541122>3.0.co;2-s
The detection and measurement of hypoxic cells in solid tumors
Abstract
The presence of viable hypoxic cells in human cancers has concerned oncologists for years. Cells in tissues that are deficient in oxygen are relatively resistant to radiation inactivation and may not be accessible to some systemic chemotherapy. The premise that hypoxic tumor cells do, indeed, control the radiocurability of some cancers is supported by some clinical evidence. The presence of hypoxic regions within tumors can be directly and indirectly inferred from invasive procedures such as oxygen electrode techniques and histologic study, respectively, but such information does not significantly contribute to current prescriptions given by oncologists for tumor treatment. Novel procedures (some of which are noninvasive) for detecting hypoxic regions within solid tumors have been proposed and are based upon two recent developments: (1) the discovery that some radiosensitizing drugs become selectively bound by metabolism to the molecules of viable hypoxic cells, and (2) the growing availability of new imaging procedures based upon positron-emission tomography, single-photon emission tomography, and nuclear magnetic resonance spectroscopy. Preliminary research results from these novel procedures are reviewed, and the potential clinical impact of each is discussed.
Similar articles
-
Modulation of prostaglandin biosynthesis in hypoxic murine mammary adenocarcinoma cells by misonidazole.Cancer Res. 1989 Jul 15;49(14):3853-6. Cancer Res. 1989. PMID: 2736527
-
Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays.Radiother Oncol. 1998 Mar;46(3):229-37. doi: 10.1016/s0167-8140(97)00186-2. Radiother Oncol. 1998. PMID: 9572615 Review.
-
Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography.Anticancer Drug Des. 1998 Sep;13(6):703-30. Anticancer Drug Des. 1998. PMID: 9755726 Review.
-
Hypoxia-mediated drugs for radiation and chemotherapy.Cancer. 1981 Aug 1;48(3):696-707. doi: 10.1002/1097-0142(19810801)48:3<696::aid-cncr2820480307>3.0.co;2-v. Cancer. 1981. PMID: 7018662 Review. No abstract available.
-
Hypoxic cell radiosensitizers in the treatment of malignant brain tumors.Neurosurgery. 1980 May;6(5):567-76. doi: 10.1227/00006123-198005000-00014. Neurosurgery. 1980. PMID: 6251398
Cited by
-
[18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model.Eur J Nucl Med Mol Imaging. 2009 Feb;36(2):209-18. doi: 10.1007/s00259-008-0907-x. Epub 2008 Aug 9. Eur J Nucl Med Mol Imaging. 2009. PMID: 18690432
-
Modeling of brain tumors using in vitro, in vivo, and microfluidic models: A review of the current developments.Heliyon. 2024 May 16;10(10):e31402. doi: 10.1016/j.heliyon.2024.e31402. eCollection 2024 May 30. Heliyon. 2024. PMID: 38807869 Free PMC article. Review.
-
Molecular and functional imaging insights into the role of hypoxia in cancer aggression.Cancer Metastasis Rev. 2019 Jun;38(1-2):51-64. doi: 10.1007/s10555-019-09788-3. Cancer Metastasis Rev. 2019. PMID: 30840168 Free PMC article. Review.
-
Strategies To Assess Hypoxic/HIF-1-Active Cancer Cells for the Development of Innovative Radiation Therapy.Cancers (Basel). 2011 Sep 15;3(3):3610-31. doi: 10.3390/cancers3033610. Cancers (Basel). 2011. PMID: 24212970 Free PMC article.
-
Positron emission tomography to assess hypoxia and perfusion in lung cancer.World J Clin Oncol. 2014 Dec 10;5(5):824-44. doi: 10.5306/wjco.v5.i5.824. World J Clin Oncol. 2014. PMID: 25493221 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources